Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials
Jennifer Jones(Dalhousie University), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Laura E. Raffals(Mayo Clinic), Fernando Velayos(Kaiser Permanente San Francisco Medical Center), Shane Devlin, Gilaad G. Kaplan(University of Calgary), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Leonard Baidoo(University of Pittsburgh Medical Center), Gil Melmed, Adam S. Cheifetz(Beth Israel Deaconess Medical Center), Brian Bressler(University of British Columbia), Miles Sparrow(Alfred Health), Patricia Kozuch(Thomas Jefferson University), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Divine Tanyingoh(University of Calgary)
Cited by 121
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k